Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1871-1880 Newer>

BusinessWeek March 28, 2005 Arlene Weintraub	Meet Mr. Rounder Equipped with two-way video capability, this robot can serve as a doctor's eyes and ears in keeping in touch with patients
BusinessWeek March 28, 2005	President Bush's IT Doctor Physician/economist David Brailer, point man for the Administration's push for e-health records, on where the planning stands
BusinessWeek March 28, 2005	Crusader for Clearer E-Info Entrepreneur Jonathan S. Bush -- yes he's related -- discusses how Web-based medical records can become a workable reality
The Motley Fool March 17, 2005 Tom Taulli	Bitter Pill for ProxyMed Technology was supposed to make health care cheaper and tech companies richer. Neither seems to be the case. While ProxyMed has dealt with its regulatory costs and is continuing to see growth in its business, there are many questions lingering for investors.
The Motley Fool March 17, 2005 Stephen D. Simpson	Patience Rewarded at Last Amylin's battle to get Symlin approved was long and difficult, but success will have its rewards. Should investors take a shot?
The Motley Fool March 17, 2005 Stephen D. Simpson	(G)Nashing of Teeth at Kensey Lower guidance and slower-than-expected FDA approval of TriActiv continue to bedevil this medical device maker.
The Motley Fool March 17, 2005 Brian Gorman	Fear Catches Up to Glaxo Glaxo's MS research is in limbo as the FDA works to calm anxieties over Tysabri. Until the fear subsides, investors are likely to suffer.
The Motley Fool March 16, 2005 Cliff Malings	Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition.
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
The Motley Fool March 15, 2005 Lawrence Meyers	Pharma's Outsourcing Elixir Pharmaceutical Product Development saves the drug companies money. Solid financials suggest it's a prescription that's working. Investors who do their due diligence may also find a few dollars earned in their brokerage accounts as well.
<Older 1871-1880 Newer> Return to current articles.